US12612385B2 Heterocyclic Compounds Targeting Pathogenic Blood Vessels
Summary
The USPTO granted Patent US12612385B2 to The Regents of the University of California on April 28, 2026, covering heterocyclic compounds and compositions for modulating PLXDC1 (TEM7) and/or PLXDC2, killing pathogenic blood vessels, and treating diseases mediated by PEDF receptors or angiogenesis. The patent contains 11 claims and names six inventors including Hui Sun, Pu Sun, Guo Cheng, Adrian Chichuen Au, and Ming Zhong. The application was filed on November 27, 2023 under application number 18519938.
“The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
The USPTO granted Patent US12612385B2, covering heterocyclic compounds and pharmaceutical compositions for modulating PLXDC1 (TEM7) and/or PLXDC2, killing pathogenic blood vessels, and treating diseases mediated by PEDF receptors or angiogenesis. The patent includes 11 claims and names six inventors.
For pharmaceutical companies and researchers, this patent establishes IP protection for University of California-developed compounds targeting vascular pathology. Any party developing similar heterocyclic compounds for PLXDC1/PLXDC2 modulation or pathogenic blood vessel treatment may need to consider licensing or design-around strategies to avoid infringement.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compounds and methods for targeting pathogenic blood vessels
Grant US12612385B2 Kind: B2 Apr 28, 2026
Assignee
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors
Hui Sun, Pu Sun, Guo Cheng, Adrian Chichuen Au, Ming Zhong
Abstract
The disclosure provides compounds, and compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using (or administering) and making the compounds. The disclosure further provides compounds or compositions thereof for use in a method of modulating PLXDC1 (TEM7) and/or PLXDC2 or killing pathogenic blood vessels. The disclosure further provides compounds or compositions thereof for use in a method of treating a disease, disorder, or condition that is mediated, at least in part, by PEDF receptors or by angiogenesis.
CPC Classifications
A61P 35/00 C07D 215/42 C07D 401/04 C07D 401/12 C07D 401/14
Filing Date
2023-11-27
Application No.
18519938
Claims
11
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.